PS
REGN icon

Principal Securities’s Regeneron Pharmaceuticals REGN Stock Holding History

Principal Securities’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$734K Buy
950
+98
+12% +$75K 0.01% 825
2025
Q4 		$658K Sell
852
-110
-11% -$74.7K 0.01% 830
2025
Q3 		$541K Buy
962
+4
+0.4% +$2.26K 0.01% 882
2025
Q2 		$503K Buy
958
+60
+7% +$33.5K 0.01% 855
2025
Q1 		$640K Hold
898
– – 0.01% 691
2024
Q4 		$640K Buy
898
+274
+44% +$230K 0.01% 686
2024
Q3 		$656K Buy
624
+140
+29% +$156K 0.02% 672
2024
Q2 		$509K Buy
484
+112
+30% +$109K 0.01% 696
2024
Q1 		$358K Buy
372
+53
+17% +$50.4K 0.01% 797
2023
Q4 		$280K Buy
+319
New +$263K 0.01% 813

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Principal Securities's REGN Position: Q1 2026 in Review

Principal Securities increased its Regeneron Pharmaceuticals (REGN) stake by 12% in Q1 2026, buying an estimated $75K and bringing the position to 950 shares worth $734K. The position accounts for 0.01% of the portfolio, ranked #825.

Principal Securities first reported a position in REGN in Q4 2023 and has held it in 10 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Principal Securities held 950 shares of Regeneron Pharmaceuticals worth $734K as of Q1 2026.
  • Principal Securities bought 98 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $75K.
  • Regeneron Pharmaceuticals made up 0.01% of Principal Securities's portfolio in Q1 2026, its #825 holding.
  • Principal Securities first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Principal Securities's 13F filing for Q1 2026, filed 13 May 2026.